Difference between revisions of "mgh:cyto-rotation"

From MGH Learn Pathology
Line 4: Line 4:
 
'''Rotation 1 (4 weeks)'''
 
'''Rotation 1 (4 weeks)'''
 
Rotation-1 curriculum is intended to be completed during four weeks of AP1.
 
Rotation-1 curriculum is intended to be completed during four weeks of AP1.
{{:mgh:cyto-week1}}<br>
+
{{:mgh:cyto-1-1}}<br>
{{:mgh:cyto-week2}}<br>
+
{{:mgh:cyto-1-2}}<br>
{{:mgh:cyto-week3}}<br>
+
{{:mgh:cyto-1-3}}<br>
{{:mgh:cyto-week4}}<br>
+
{{:mgh:cyto-1-4}}<br>
 +
{{:mgh:cyto-1-5}}<br>
 +
{{:mgh:cyto-1-6}}<br>
 +
{{:mgh:cyto-1-7}}<br>
 +
{{:mgh:cyto-1-8}}<br>
 +
{{:mgh:cyto-1-9}}<br>
 +
{{:mgh:cyto-1-10}}<br>
 +
{{:mgh:cyto-1-11}}<br>
 +
{{:mgh:cyto-1-12}}<br>
 +
{{:mgh:cyto-1-13}}<br>
 +
{{:mgh:cyto-1-14}}<br>
 +
{{:mgh:cyto-1-15}}<br>
 +
{{:mgh:cyto-1-16}}<br>
 +
{{:mgh:cyto-1-17}}<br>
 
<br>
 
<br>
 
'''Rotation 2 (2 weeks)'''
 
'''Rotation 2 (2 weeks)'''
 
Rotation-2 curriculum is advanced, and intended to be completed during two weeks of AP-2.
 
Rotation-2 curriculum is advanced, and intended to be completed during two weeks of AP-2.
{{:mgh:cyto-week5}}<br>
+
{{:mgh:cyto-2-1}}<br>
{{:mgh:cyto-week6}}<br>
+
{{:mgh:cyto-2-2}}<br>
 +
{{:mgh:cyto-2-3}}<br>
 +
{{:mgh:cyto-2-4}}<br>
 +
{{:mgh:cyto-2-5}}<br>
 +
{{:mgh:cyto-2-6}}<br>
 +
{{:mgh:cyto-2-7}}<br>
 +
{{:mgh:cyto-2-8}}<br>
 +
{{:mgh:cyto-2-9}}<br>
 +
{{:mgh:cyto-2-10}}<br>
 
<br>
 
<br>
 
'''Welcome to Cytology'''
 
'''Welcome to Cytology'''

Revision as of 14:52, July 2, 2020

  • Clinical Rotations
    • Anatomic Pathology residents spend four weeks on the cytology service during AP1 (rotation-1), and six weeks during AP2 (rotation-2). Each week that you are on the cytology service, you will be assigned to work a faculty member who is on-service, and you will have an opportunity to review and diagnose current cytology cases. Additionally, there are structured learning modules for rotation-1 and rotation-2.


Rotation 1 (4 weeks) Rotation-1 curriculum is intended to be completed during four weeks of AP1.

Lectures

Cytopathology Laboratory

  • Location: Warren 125 (6-3980) – Main Cytology Office: supervisor’s office, cytotechnologists’ stations, cytopathology fellow desks (4-1422), secretaries and multi-headed microscope
  • Warren 113 (4-1424) – Cytology Specimen Preparation Room: specimen drop off
  • Wang 270-FNA exam room (4-1077)
  • Wang 290- FNA waiting room on ACC-2
  • Staff:
  • Cytopathologists:
  • Cytotechnologists - Peter Brown, Heather Grant, Diane Kuebler, Marilyn Nutter, Mary Pinheiro-Rego, Lisa Ring, and Caitlin Eno
  • CLA Secretaries – Bernadette Femino and Diane White
  • Lab Preparatory Technologists - Ernest Li, Shirley

Hours of Operation:

  • The Cytopathology Laboratory is open Monday through Friday:
    • For reports and information: 8:30 a.m. - 5:00 p.m.
    • For specimen preparation: 7:30 a.m. – 5:00 p.m.
  • After Hours Policy

Services Offered

  • Diagnostic interpretation of cytology specimens:
  • Fine needle aspiration biopsy (FNAB) service:
  • Rapid Evaluation and Interpretation (Rapids):

Critical Values for Cytopathology

1. The pathologist (or nominated designee) will transmit a result urgently to the attending physician or another licensed caregiver who can take action on the results, ideally by telephone, under the following general circumstances:
2. The following case types constitute a critical value in cytology:


  • To document notification, insert Coded Comment: “NOTIFY”[F8}
  • To flag the case as a critical value case, check the
  • Retrieval Flag: CVR [critical value report]
  • GYN cases: staff/reflex tab
  • Non-GYN case: QA tab

Cytology Specimens

Specimen types:

Gynecologic (Pap smears):
Non-gynecologic:

Specimen Collection

Cytology test orders are only accepted from individuals authorized to do so in accordance with law and regulation.

  • Gyn specimens (Pap smears):
  • Non-gyn specimens:

Specimen Delivery

  • Between 7:30 a.m. and 5:00 p.m. (Monday through Friday), specimens should be delivered to the cytopreparatory laboratory area (Warren 113). When the laboratory is closed, specimens should be taken to the Core lab on Gray 5 between the hours of 5 p.m.-7:30 a.m. Monday-Friday and on weekends/holidays.
  • Verbal Orders:

Specimen Rejection Policy

Specimens received in the Cytopathology Laboratory having identification information that cannot be verified will not be processed. Two patient identifiers must be provided and verified as correct before laboratory specimens will be processed or tested. Both container or slides and requisition must be labeled. The labels must contain the patient’s full name and/or medical record number and/or date of birth. Identifiers must match one another. Specimens that are not readily replaced and have identification discrepancies will be processed upon completion of a Specimen Release form and corrected requisition by an individual authorized to take such responsibility. (See cytology manual for complete procedure).

Rapid on site evaluation and interpretation

  • Rapid interpretations are performed on most FNABs performed by the pathologist or other physicians (radiologist, gastroenterologist, pulmonologist, surgeon) in order to guide the procedure. The rapid is intended to assess if the specimen is representative, to determine the need for additional passes and to correctly triage the material for special studies if need be (flow cytometry, cultures, electron microscopy or a request for core biopsy by the radiologist). A definitive diagnosis is not necessary at the time of rapid interpretation although this may be possible in many cases.
  • For radiologically obtained FNABs, a cytotechnologist selects one smear per pass, stains the smear with H&E and evaluates the smear. When the tech estimates that the smear is representative, the pathologist is called to give the rapid interpretation.
  • Rapid interpretations of previously submitted specimens or specimens obtained by the clinician will be performed only if the rapid interpretation will affect current patient care.
  • Please send ALL specimens from the procedure for each patient to cytology at the same time to avoid delays in processing.

FNA Tissue Triage For Radiologically Guided CT/US Guided Biopsies

Perform FNA first
Perform core biopsy second

Tissue Triage for EBUS Procedures

Brushing
Bronchial wash and lavage
EBUS-FNAB (do not need rapid interpretation if doing a concurrent frozen section of core biopsy)

Cytology service page

Warning: Display title "1-2 Cytomorphology: Basic Concepts" overrides earlier display title "1-1 Cytopathology Personnel, Procedures and Policies".

Cell classification by morphology

  • Cytology diagnosis depends on the appearance of individual cells usually devoid of architectural detail or extracellular matrix. Because the cells are analyzed at much higher magnification than takes place for histology, you need to shift your focus to details overlooked in histologic exams.
  • Nuclear morphology provides information on the level of cellular activity while the cytoplasm provides clues to the cell differentiation or cell type.
  • Cell shape will vary in cytology samples depending on how the sample was obtained. Exfoliated cells suspended in liquid fixative often have a round shape. Cells that have been plucked from their tissue either by abrasion (brushing, scraping) or fine needle aspiration may retain their native shape (rectangular glandular cells, polygonal squamous cells).
  • Epithelial cells
    • The quality of the cytoplasm offers clues as to cell origin: cytoplasm of glandular cells is pale staining with one vacuole or many micro vacuoles containing glandular secretions; squamous cells usually have a more dense, uniformly stained cytoplasm and may show a linear quality surrounding the nucleus. Nuclei are generally “euchromic” that is the chromatin is of a normal intensity. In cytology preparations from women, the inactive X chromosome may be seen as a small dense dot on sitting on the nuclear membrane, known as the Barr body.
  • Glandular cells
5.8_Huntington_Disease.jpg one_ciliated_endocx_cell_60x.jpg
Single Endox Cells
One Ciliated Endox Cells

When single, glandular cells have a rectangular or square shape. The cytoplasm is delicate and the nucleus tends to be round with finely distributed (open or vesicular) chromatin. A small nucleolus may be present. The nucleus tends to be present at the end of cytoplasm nearest the prior attachement to the basement membrane. This site of attachement may appear as a cytoplasmic tail where the cell was detached from the basement membrane.Glandular cells in groups can appear as:

1. Flat sheets with uniform placement of cells in a “honey comb” arrangement similar to a bee hive. By shifting the plane of focus on a glandular sheet, either the mucin-filled cytoplasmic pole or the nuclear pole will be in focus.

1a_honecomb_gld_cells_40x.jpg 1b_real_honeycomb_.jpg
cells in honey comb arrangement

2. Aligned groups of rectangular columnar cells are said to have a picket fence arrangement. The columnar cells may have a row of cilia attached to a terminal bar at one short end of the cell.

2a_gld_cells_picket_fence_60x.jpg 2b_spaced-picket-fence-dogear-473x314.jpg
Picket fence

3. Clustered groups or three dimensional groups of cells with rounded borders often with visible cytoplasmic vacuoles may be abradedor shed from hyperplastic epithelia. Glandular lumens may be visible.

3_goblets_in_benign_ec_C02B11922.jpg


Squamous Cells
4. Squamous cells when single usually appear as flat polygonal cells. The size of squamous cells varies according to the layer of origin within the epithelium and other factors such as hormone stimulation. The Papanicolaou stain differentially colors the cytoplasm according to the stage of keratinization: younger cells appear more blue-green, more fully keratinized cells turn pink and finally appear orange.

4_polygonal_sq_cells_40x.jpg 5_keratinizing_sq_ca.jpg
Polygonal squamous cells
Orangeophilic fully Keratinized squamous cells

The nuclei of the squamous cells vary from larger and round with fine (open) chromatin in less mature cells to pyknotic (dense, dark) and small in superficial cells to a complete absence of nuclei in anucleate squames.

6_intermediate_sq_cell_60x_only.jpg 7_superficial_sq_cell_60x_2.jpg 7b_anucleate_squames_20x_DQ.jpg
Intermediate squamous cell with open chromatin
Superficial squamous cell with dense pykonic chromatin
Anucleate squames

Squamous cells in groups often appear flattened; intercellular junctions can be identified.

8_sq_cells_intercellular_bridges_JH.jpg

Mesothelial cells

  • These are cuboidal cells that occur in sheets, or when shed in body cavity fluids as rounded cells usually with a dense perinuclear area and paler periphery due to microvilli. When juxtaposed one to another, an intercellular space is visible due to the microvilli.

Mesenchymal cells other than adipocytes often have a spindled or elongate shape. Striations may be seen in skeletal muscle cells

Leukocytes are rounded cells; nuclear shape provides a clue to the cell type: bilobed eosinophils (granules not always obvious), poly lobed neutrophil, reniform shaped macrophage.

Cytoplasmic and extracellular pigment:

  • Melanin – brown, dusty to granular on Pap, deep blue with Giemsa
  • Hemosiderin – coarsely brown on Pap
  • Hematoidin (an intermediate breakdown product of hemoglobin) - yellow
  • Bile – deep golden yellow


Morphology of cell response to injury

  • Apoptosis
  • Necrosis
  • Reactive nuclear and cytoplasmic changes:
    • Nuclear enlargement B12 deficiency
    • Mitoses
    • Enlarged nucleoli
    • Multinucleation
    • Cell enlargement
    • Cytoplasmic vacuolization and polychromasia


Cytomorphology of malignancy

Nucleus Multiple nuclear abnormalities occur in malignant cells. No every malignant tumor will show all features and a critical number of features (although there is no magic number) need to be identified before one can say with confidence “this is a malignant cell”. Listed below are the most common changes:

  • Nuclear enlargement
  • Increased nuclear to cytoplasmic ratio
  • Nuclear membrane irregularity
  • Chromatin abnormalities: hyperchromasia, coarse irregular chromatin clumping, hypochromasia
  • Abnormal nucleoli: excessively large, irregularly shaped, multiple
  • Intranuclear inclusions
  • Nuclear grooves or creases
  • Abnormal mitoses

Cytoplasm and cell arrangement

  • Nuclear abnormalities are most critical to the cytologic diagnosis of malignancy, but cytoplasmic and architectural features also occur.
  • Depending on the degree of differentiation the malignant cell will vary from near normal in size to extremely large. The malignant cells may vary in size among themselves (anisocytosis).
  • Orderly cell arrangement is often lost in malignancy, such as the “drunken honeycomb” pattern seen in ductal carcinoma of the pancreas.
  • Loss of cell to cell adhesion often occurs in carcinoma, especially in adenocarcinoma. Paradoxically in some squamous cell carcinomas the malignant squamous cells may be seen in large cohesive groups while abraded normal squamous cells occur as single cells.
  • Necrosis (also known as tumor “diathesis”) may be apparent on cytology samples as anuclear cellular debris and fibrin present as a film in the background of smears or as material clinging to cell groups in liquid based cytology preparations.

Cytology service page
Warning: Display title "1-3 Gyn Cytology Basics" overrides earlier display title "1-2 Cytomorphology: Basic Concepts".

Lectures

  • Lecture: Normal cervical cytology by Dr. D. Wilbur
  • Lecture: HPV testing, QA/QC by Dr. D. Wilbur
  • Test platforms/specimen processing and triage
    • GYN samples are submitted for processing as liquid based specimens. Samples are collected using one of the recommended SurePath collection devices (broom or combination brush/spatula). After the sample is obtained, the head of the collection device is snapped off and put into the SurePath preservative vial. If HPV testing was requested, the test will be done using the tube that was produced during the processing of the SurePath vial.


GYN Cytology: Screening for Cervical Cancer Basic Overview

  • HPV and cervical cancer: an overview
  • Guidelines for cervical cancer screening
  • Obtaining cervical cytology sample (Pap smear)
  • Primary screening method
  • Bethesda system for reporting gyn cytology and cytology report structure including adequacy
  • Test platform for gyn cytology: instruments, stains
  • Resident Training in Primary Screening: See Marilyn Nutter
  • All residents are to screen 20 Pap tests as primary screeners.

Cytology service page
Warning: Display title "1-4 Body Cavity Fluids" overrides earlier display title "1-3 Gyn Cytology Basics".

Body Cavity Fluids Cases:

Ivan Chebib MD, Amy Ly MD, Ron Arpin SCT

  • Indications for cytology examination
  • Procuring the specimen
  • Test platforms/specimen processing and triage
  • Reporting and terminology

Basic cytomorphology:

Normal mesothelial cells – MN05-G13557
Reactive mesothelial cells – N13-8012
Mesothelioma – N12-12597
Metastatic adenocarcinoma – lung – N13-7980
Metastatic adenocarcinoma – breast – C99-T533
Metastatic adenocarcinoma – ovary – N13-6042 and N13-5843
Metastatic adenocarcinoma – GI –C98-N39001
Melanoma –C99-W27742
Lymphoma – N13-6082

Cytology service page
Warning: Display title "1-5 Cerebrospinal Fluid (CSF)" overrides earlier display title "1-4 Body Cavity Fluids".

  • Ivan Chebib MD, Amy Ly MD, Ron Arpin SCT
  • Reading: Cibas 4th Ed. Chapter 6; Bibbo/Wilbur 4th Ed. Chapter 16
  • Questions: When you have completed unit 1-5 go to the Assessment tab and answer the question.
  • Dr. Tambouret CSF Lecture
  • Indications for cytology examination
  • Procuring the specimen
  • Test platforms/specimen processing and triage
  • Reporting and terminology

Introduction

CSF is produced by the choroid plexus in lateral, 3rd and 4th venticles by passive filtration and active transport. The CSF circulates through the subarachnoid space from the ventricles to bathe the brain and spinal cord. The Chorioid plexus consists of frond-like villous projections of vessels and pia mater that protrude into the ventricles. Specialized ependymal cells known as choroidal epithelium overlies the villi. The CSF is resorbed in the archanoid villi in the superior sagittal and intracranial venous sinuses and around spinal nerve roots. The arachnoid villi function as one way valves.

CSF Circulation

Indications for cytology examination

The CSF is examined in many clinical situations. The CSF is submitted for cytology examination usually only when a malignancy is suspected, either metastatic solid tumors or lymphoma/leukemia. Leptomeningeal (LM) metastasis is diagnosed in about 5% of patients with metastatic carcinoma. The tumors most likely to involve the CSF in order of frequency are breast, lung, melanoma, GI tumors and carcinoma of unknown primary. Primary brain tumors can involve the CSF. Forty percent of primary CNS lymphomas will have LM involvement

Accuracy

The sensitivity of CSF cytology for malignancy ranges from 80 to 95%. False-positive results are very rare, but false negative (FN) results are not uncommon. To minimize FN a minimum of 10 cc CSF should be sent to cytology, the sample should be processed promptly and a repeat sample obtained if malignancy suspected but results are negative. One study showed increasing sensitivity with repeat samples of 71% for first, 86% for second, 90% for third and 98% for > 3 samples (Glantz MJ et al. Cancer 1998;82:733).

Procuring the CSF sample

Usually the CSF is obtained by lumbar puncture. Samples may also be obtained from an Ommaya resevoir which consists of a subcutaneous pouch connected to a cannula ending in one of the lateral ventricles.

Test platforms/specimen processing and triage

Currently in the MGH lab two cytospin slides are prepared from a fresh CSF sample. One slide is fixed in 95% ethanol immediately after preparation and stained with Papanicolaou stain. The second is allowed to air dry and then is stained with rapid Giemsa stain used at MGH.

IMG_0737.MOV

The CSF Cytology Report

The results are report as one of four categories: Negative for malignant cells, Atypical (low degree of suspicion for malignancy), Suspicious (a high degree of suspicion for malignancy) or Positive for malignant cells. Over 90% of CSF samples are reported as Negative.

Basic cytomorphology

Normal CSF – N13-7784
Lymphoma – N13-7674
Melanoma –N11-14115
Metastases – MN05-X04913

Cytology service page
Warning: Display title "1-6 Urine Cytology: R. Tambouret MD, E. Brachtel MD, Ron Arpin SCT" overrides earlier display title "1-5 Cerebrospinal Fluid (CSF)".

Lecture Slides


  • Indications for cytology examination
  • Procuring the specimen
  • Test platforms/specimen processing and triage
  • Reporting and terminology


Basic cytomorphology

Normal urothelial cells – N13-593

  • Normal urothelial cells vary greatly in numbers, sizes, and shape
  • Mononuclear urothelial cells are cuboidal, and parabasal-like or polyhedral
  • Surface umbrella cells are large, often multinucleated, with convex surface corresponding to the lumen of the bladder
  • Cytoplasm blue to grey and occasionally shows fine vacuolization
  • Round to ovoid nuclei are centrally located with finely granular chromatin and small nucleoli
  • Urothelial cells may show thin cytoplasmic tails (cercariform cells)
1-6_single%2Btransitional%2Bcells.jpeg 1-6_umbrella%2Bcell.jpeg
Single transitional cells: Urothelial or transitional cells have dense cytoplasm and round, central nuclei
Umbrella cells are often multinucleated
1-6_nonspecific%2Beosinophilic%2Binclusion.jpeg 1-6cercariform%2Bcells.jpeg
Non-specific eosinophilic inclusions are commonly identified in degenerating urothelial cells
Cercariform cells have an elongated cytoplasmic process with a blunted end. The cells are named for their resemblance to the cercaria developmental stage of trematodes


Urothelial clusters and papillary fragments – N13-7330

  • Approximately 20% of normal voided urine samples may contain urothelial clusters
  • This finding is considerably enhanced in bladder washings, catheterized urine, and brushings due to the propensity of urothelium to exfoliate
  • The interpretation of papillary urothelial neoplasm should be made with caution and needs to be correlated with other findings
  • Cells in the clusters show nuclei that may appear hyperchromatic or pale and may contain one or more nucleoli
  • Occasionally may see a cap of umbrella cells on one side of these clusters, especially in cell groups abraded by instrumentation
1-6_cysto%2Burine.jpeg


Squamous and glandular cells – N13-7020

  • Squamous cells, in variable numbers, may be present as contaminants from external genitalia or may appear as a component of normal bladder being shed from the trigone
  • Secretory columnar cells and cells from intestinal metaplasia may be seen as part of normal metaplastic change or as a component of cystitis glandularis
1-6_squamous_in_urine.jpeg 1-6_glandular%2Bcells%2Bin%2Burine.jpeg
Squamous cells in urine are common, especially in women from genital tract contamination
Columnar glandular cells are unusual in urine specimens; the cells probably derive from cystitis glandularis


Renal casts – N13-7187

  • Hyaline and granular casts may be seen even in patients without overt evidence of renal pathology
  • Hyaline casts are composed of amorphous, eosinophilic proteinaceous material while the granular casts are composed of degenerated red blood cells or renal tubular cells
  • Renal tubular cells are small columnar cells occurring in narrow sheets in the shape of the tubule or as single cells
1-6_waxy%2Bcast.jpeg


Ileal conduit urine – N13-7328

  • Ileal conduit urine is usually obtained for surveillance
  • Since the colonic mucosa is exposed to a hostile and toxic environment, degenerative changes predominate
  • Cells resemble macrophages, there is karyorrhexis, pyknosis, and abundant red inclusions in the cytoplasm
  • Cytoplasmic debris and bacteria are seen in the background
  • Detection of malignancy may be challenging in this setting
  • Diagnosis should be based on cells with characteristic features of malignancy
1-6_ileal%2Bloop%2Burine.jpeg


Candida albicans – N13-7605

  • Candida is the most common fungal infection and is seen as pseudo-hyphae or spores
  • It may occur as a contaminant from the vagina in female patients
  • However- the presence of fungal organisms in cases of renal transplant or immunosuppression denotes true infection, and requires appropriate management


Human Polyoma Virus – N13-6375

  • Infection with the polyoma virus is acquired early in life
  • Activation occurs for unknown reasons or in the setting of immunosuppression due to transplantation, chemotherapy, AIDS, diabetes, etc
  • Infected cells vary in size but generally have an increased nuclear to cytoplasmic ratio; viral cytopathic effect is confined to the nucleus
  • Inclusions of polyoma virus are large basophilic opaque and intranuclear that fill the nucleus leaving only a thin rim of residual chromatin or net-like (reticular) filaments of chromatin
  • Polyoma virus changes can be mistaken for urothelial cancer and therefore these cells are called "decoy cells"; unlike carcinoma, nuclei infected with the polyoma virus tend to be round with a smooth nuclear membrane
  • Polyoma virus may coexist with cancer
1-6_polyoma%2Bvirus.jpeg


Catheterization/lithiasis changes – N13-5377

  • Presence of stones can result in large urothelial clusters and papillary fragments with marked variation in the shape and size of the urothelial cells and hyperchromasia
  • Sometimes the atypia associated with lithiasis is so severe that further work-up to exclude malignancy is necessary
  • Cytologically, there is nuclear enlargement, pleomorphism, increased N/C ratio, coarse dense chromatin, prominent nucleoli, occasional mitoses, degeneration and necrosis
  • Catheterization and instrumentation of the bladder will cause sheets and groups of urothelial cells to be sheared off; this is known as instrumentation effect and should not be confused with low grade papillary carcinoma
1-6_clusters%2Bin%2Bbld%2Bwash.jpeg 1-6_lubricant%2Bin%2Bbld%2Bwash.jpeg
Clusters of urothelial cells may occur in urine secondary to instrumentation effect or to the presence of stones, in which case the sign out is "negative". At MGH unexplained clusters are designated as "atypical", although the likelihood of underlying low grade papillary TCC is remote
Lubricant may be present as acellular blue material in the background of an instrumented urine


Urothelial carcinoma – N13-7019 and N13-6041

  • Cytologically, high grade urothelial carcinomas are relatively easy to diagnose with a high degree of sensitivity and specificity due to the presence of anaplastic cells
  • May see cellular preparations with abundant atypical urothelial clusters and single malignant cells in the background
  • Occasionally the samples may be sparse
  • Cells have high N/C ratios, with marked pleomorphism
  • Nuclei are often eccentric with hyperchromatic coarse chromatin and large irregular nucleoli
  • Nuclear membrane is thickened and occasional mitoses may be seen
  • Cytoplasm is poorly demarcated and cyanophilic
  • Overall, low grade urothelial carcinoma has a low diagnostic sensitivity and specificity because low grade tumors are diploid and lack the striking hyperchromasia of the high grade tumors.
  • These tumors are cytologically bland, often impossible to distinguish from benign urothelial cells. three dimensional urothelial clusters in a voided urine, especially those with fibrovascular cores (a rare finding) are worrisome for low grade papillary TCC
  • Cells in these clusters may have high N/C ratios with nuclei bulging out of the cytoplasm
  • Nuclei may be irregular and may appear to have notches or grooves but more often than not the cells cannot be deemed worse than “atypical” , a diagnosis considered by urologists to be “negative”
  • Chromatin is granular and evenly distributed
  • Nucleoli are indistinct or absent
1-6_high%2Bgrade%2BTCC.jpeg


Adenocarcinoma/squamous cell carcinoma

  • Primary adenocarcinomas of the bladder are rare, constituting less than 2% of all bladder cancers
  • The cells have typical features of malignancy with large eccentrically placed nuclei with open chromatin and prominent nucleoli
  • Cytoplasm may be abundant and may show mucin vacuoles
  • Adenocarcinoma cells may be a component of a high grade urothelial carcinoma
  • Primary squamous cell carcinoma of the bladder may be secondary to Schistosomiasis infection


Metastases – N13-3279

  • On rare occasions, locally invasive extravesical carcinoma may invade the bladder wall and shed into the urine, such as cells of prostatic adenocarcinoma
  • Distant metastases may also be found in the urine, such as carcinomas, melanomas or lymphomas
  • Tumors of the female genital tract such as squamous carcinoma and adenocarcinoma of the cervix, and high grade epithelial tumors of the ovary and colon may also be occasionally seen due to direct extension of the tumors through the bladder wall

Cytology service page
Warning: Display title "1-7 Respiratory Cytology: W.S. Black-Schaffer MD, Mary Rego CT" overrides earlier display title "1-6 Urine Cytology: R. Tambouret MD, E. Brachtel MD, Ron Arpin SCT".

Lectures

  • Indications for cytology examination
  • Procuring the specimen
  • Test platforms/specimen processing and triage
  • Report


Basic cytomorphology

Cytology Respiratory Specimens –MN05-J8970
Normal Respiratory Cytology –MN05-X13303
Alveolar macrophages –MN06-M2366
Granulomatous Inflammation –MN05-F5872
Chondroid Hamartoma–C03-C14116
Candida and Actinomyces from oral contamination
Squamous Cell Carcinoma –C92-8306 and MN06-324
Bronchogenic adenocarcinoma –C00-A43961
Bronchioloalveolar Carcinoma –C01-W33204
Small Cell Carcinoma –C03-T32870 and MN04-G5451
Carcinoid –C02-M34743
Metastatic malignancy –MN07-T9423, MN07-T9423 and C97-B18744

Cytology service page
Warning: Display title "1-8 Thyroid Cytology: W. Faquin MD PhD, Lisa Ring CT" overrides earlier display title "1-7 Respiratory Cytology: W.S. Black-Schaffer MD, Mary Rego CT".

Lecture slides:


Indications for cytology examination
Procuring the specimen
Test platforms/specimen processing and triage
Reporting and terminology


Basic cytomorphology


Benign Thyroid –THY4-16

  • Adequacy: must meet a minimum of 6 groups of well-visualized follicular cells with at least 10 cells per group
  • Abundant watery colloid in background
  • Scattered fragments of macrofollicles
  • Normal follicular cells contain small amounts of granular cytoplasm with a small, dark round central nucleus
  • May find few macrophages (foam cells)
  • Reactive Hurthle cell changes can be seen
1-8-1_watery_colloid.jpg 1-8-2_macrofollicle_benign.jpg
Watery colloid is usually a benign feature, with the exception of papillary thyroid carcinoma
Macrofollicles
1-8-3_benign_follicular_lesion.jpg 1-8-4_ben%2Bfollicular%2B2.png
Single Endox Cells
Macrofollicles and colloid, consistent with a benign thyroid nodule


Hashimoto Thyroiditis (chronic lymphocytic thyroiditis) –THY2-15

  • 2 cell types NEEDED for diagnosis: lymphocytes and Hürthle cells!
  • Lymphocytes embedded within the groups of follicular/Hürthle cells are a characteristic feature
  • Hürthle cells may show increased N/C ratio, prominent nucleoli and nuclear irregularity
  • Small amounts of dense colloid may be present
  • Squamous metaplastic cells, foam cells, giant cells, fibrous tissue, granulomas and calcifications may be present
  • Tingible body macrophages and germinal center fragments
  • Plasma cells
Hurthle cells in Hashimoto thyroiditis are easily recognized as benign


Papillary Carcinoma –THY2-26

  • Increased cellularity!
  • 3D papillary architecture or monolayered sheets
  • Intranuclear inclusions
  • Nuclear grooves (less specific for diagnosis)
  • Pale even chromatin
  • May see small but prominent nucleoli
  • Variation in nuclear size and shapes
  • Generally abundant cytoplasm that is either dense and homogenous or granular but well defined borders
  • Blood in background
  • SCANT colloid (or very little--dense, bubble-gum appearance)
  • Psammoma bodies
1-8-6_PTC.jpg 1-8-7_PTC_syncytial_groups.jpg
Papillary thyroid carcinoma (PTC) often results in a malignant or suspicious diagnosis
PTC with syncytial groups
1-8-8_PTC_longitudinal_nuclear_grooves.jpg 1-8-9_PTC%2Bfollicular%2Beasy.png
PTC with longitudinal nuclear grooves
Easier to identify follicular variant of PTC
1-8-10_PTC_follicular_harder.jpg 1-8-11_PTC%2B2.jpeg
Harder to identify follicular variant of PTC
PTC with abundant cytoplasm


Medullary Carcinoma –THY4-05

  • Malignant parafollicular C-cells
  • CELLULAR SMEAR with isolated cells and some loosely cohesive cell clusters
  • Mild to absent pleomorphism
  • Can have a neuroendocrine-like appearance--salt & pepper chromatin pattern
  • Intranuclear pseudoinclusions are also present
  • Cytoplasm is finely granular and may contain red granules (seen in 30% of cases with Diff-Quik)
  • Cell types include plasmacytoid, spindle, polygonal, round or triangular
  • Amyloid--looks like dense colloid (stains bright green with Congo Red)
Medullary thyroid carcinoma


Undifferentiated (Anaplastic) Carcinoma –THY5-19

  • Increased cellularity
  • Malignant features
  • Epithelioid cells present in groups and singly--round, spindled or polygonal in shape
  • Pleomorphic nuclei--may see bi or multinucleated cells
  • Increased N/C ratios
  • Cytoplasm is moderate to abundant, basophilic and well-defined which sometimes may be vacuolated or granular
  • Prominent nucleoli
  • Irregular, clumped, coarse chromatin patterns
  • May find intranuclear inclusions
  • May see mitoses
  • Background is usually rich in necrotic debris and blood

Cytology service page
Warning: Display title "1-9 Salivary Gland and Head and Neck Cases: W.C. Faquin MD PhD, Lisa Ring CT" overrides earlier display title "1-8 Thyroid Cytology: W. Faquin MD PhD, Lisa Ring CT".

General

Indications for cytology examination
Procuring the specimen
Test platforms/specimen processing and triage
Reporting and terminology

Basic cytomorphology


Benign Salivary Gland Tissue – SG2-05

  • Acinar structures separated by adipose tissue
  • Serous acinar cell cytoplasm contains zymogen granules (basophilic on Diff-Quik): produce enzymes
  • Mucinous cells are tall, columnar with abundant, finely granular or vacuolated cytoplasm and basally located small round nuclei
  • Ductal epithelium has scant cytoplasm and round to oval small, dark nuclei
  • Myoepithelial cells are rarely seen as an isolated component in normal tissue and they are closely associated with epithelial structures
  • Myoepithelial cells have oval to plasmacytoid shape, oval to round nuclei, moderate amounts of cytoplasm or as bare nuclei
  • Other variable cell types: oncocytes (increase with age), metaplastic squamous cells, sebaceous cells, lymphoid cells
FNA sample of a normal salivary gland, depicting intercalated ductal cells and acinar cells


Pleomorphic Adenoma –SG2-22

  • Most common benign tumor of parotid gland (75%), well-circumscribed mass
  • Aspirates have a thick, gelatinous consistency 3 components NEEDED for diagnosis: epithelial cells, myoepithelial cells and matrix
  • Matrix- fibrillar with ragged edges and embedded myoepithelial cells
  • Dusty purple stain on pap stain: magenta using air dried preps
  • Slight atypia in stroma may signify degeneration
  • Epithelium arranged in loosely cohesive groups, flat sheets and glands
  • Admixture of cellular and stromal components shows a characteristic blending, not seen in other salivary gland tumors
  • Myoepithelial cells may be associated with epithelial groups or may appear as "naked" nuclei in the background of smears
  • May see metaplastic squamous cells or oncocytes surrounding tumor
1-9-2_pleomorphic%2Badenoma.jpeg 1-9-3_pleomorphic%2Badenoma%2Bw%2Bfibrillar%2Bmix.jpeg
Pleomorphic adenoma with fibrillar matrix
1-9-4_pleomorphic%2Badenoma%2Bw%2Bstellate%2Bmyoepithelial%2Bcells.jpeg 1-9-5_metachromatic%2Bmatrix%2Bpleo%2Badenoma.jpeg
Metachromatic stroma in pleomorphic adenoma. Diff-Quik.
1-9-6_bland%2Bmyoepithelial%2Bcells%2Bpleiomorphic%2Badenoma.jpeg 1-9-7_plasmacytoid%2Bmyoepithelial%2Bcells%2Bpleo%2Badenoma.jpeg 1-9-8_spindled%2Bmyoepithelial%2Bcells%2Bpleo%2Badenoma.jpeg
Groups of bland myoepithelial cells in pleomorphic adenoma
Plasmacytoid myoepithelial cells
Spindled myoepithelial cells


Warthin Tumor –SG9-12

  • 5-10% of salivary gland tumors, most often in tail of parotid gland, sometimes bilateral
  • Cystic dark fluid on aspiration
  • History of slow growing mass
  • Monolayered sheets of oncocytes with distinct cell borders and background lymphocytes and mast cells
  • Lymphocytes my be in aggregates or spread in background of smears
  • May see squamous metaplastic cells surrounding tumor
Warthin tumor cells demonstrating a combo of oncocytes, lymphocytes, and debris


Adenoid Cystic Carcinoma – SG5-21

  • 3-5% salivary gland tumors, common in minor and submandibular glands, malignant
  • Increased cellularity!
  • Crowded acellular 3D sheets of cribriform structures
  • Finger or cup-shaped groups an important feature
  • Small, round, uniform, bland basaloid cells with high N/C ratio, nuclear molding, scant cytoplasm and small distinct nucleoli surrounding mucoid balls, DQ stains red balls of mucopolysaccharide
  • Necrosis present in 50% of cases
1-9-10_adenoid%2Bcystic%2BCA.jpeg 1-9-11_adenoid%2Bcystic%2BCA%2B2.jpeg
Another image of classic cribiform "Swiss cheese" adenoid cystic carcinoma
1-9-12_classic%2Badenoid%2Bcystic%2BCA.jpeg 1-9-13_classic%2Badenoid%2Bcystic%2BCA%2B2.jpeg 1-9-14_adenoid%2Bcystic%2BCA%2Bwith%2Bhigh%2Bgrade%2Btrans.jpeg
Classic adenoid cystic carcinoma
Another image of classic adenoid cystic carcinoma
Adenoid cystic carcinoma with high grade transformation


Head and Neck
Branchial Cleft Cyst (lymphoepithelial cyst) – SG-04

  • Thick yellow fluid on aspiration
  • Lateral cyst--occurs along anterior border of sternocleidomastoid muscle (ear to clavicle)
  • Can occur in parotid in HIV patients
  • Occasionally bilateral
  • History of painless, firm mass with rapid growth; DDX: SCCA=may require a biopsy to confirm!
  • Cysts lined by squamous cells, glandular cells or both cell types
  • Epithelium surrounded by dense lymphocytic infiltrate
  • Nucleated and anucleated squamous cells with keratinization shed into cystic space
  • Acute and chronic inflammation
  • Dirty granular background

Cytology service page
Warning: Display title "1-10 Liver Cytology: M Pitman MD, J Misdraji MD, Marilyn Nutter CT" overrides earlier display title "1-9 Salivary Gland and Head and Neck Cases: W.C. Faquin MD PhD, Lisa Ring CT".


Indications for cytology examination for liver
Procuring the specimen (liver)
Test platforms/specimen processing and triage (liver)
Reporting and terminology (liver)


Basic cytomorphology


Regenerative, Dysplastic and Benign Neoplastic Hepatocellular Nodules – N12-12133 reactive, N12-4918 and N12-6339

  • Hepatocytes arranged in jagged irregular clusters, small clusters, short rows and singly (depending on regenerative, dysplastic or neoplastic nature)
  • No peripheral endothelium
  • Clusters rarely have transgressing endothelium (except for neoplastic aspirates)
  • Reactive hepatocytes show sibling polymorphism with normal nuclear-to-cytoplasmic ratio (1/3) and frequent binucleation
  • Sporadically placed large, atypical cells with mild pleomorphism of nuclear size but normal nuclear-to-cytoplasmic ratio (in dysplastic hepatocytes with large cell change)
  • Small uniformly monotonous hepatocytes with increased nuclear-to-cytoplasmic ratio and nuclear crowding (in dysplastic hepatocytes with small cell change)
  • Variably prominent nucleoli but no macroeosinophilic nucleoli
  • Cytoplasm is generally abundant (except in small cell change) and granular but may show fatty change, lipofuscin pigment, or iron deposition
  • Bile duct epithelium present (except in LCA)
  • Core biopsies provide specific diagnosis: Reticulin stain shows retention of 1 to 2 cells thick hepatic plate framework on cellblock; unpaired arterioles in parenchyma for LCA; bile duct proliferation and scar for FNH
1-10-1_benign_hepatocytes_and_ductal_cells.N12-12133..jpg 1-10-2_reactive_hepatocytes._N12-12133.jpg
Reactive hepatocytes
1-10-3_reactive_hepatoctes_2.N12-133.jpg 1-10-4_benign_liver_with_reticulin_stain.N12-4918.jpg
Benign liver (cirrhosis) with reticulin stain


Well-differentiated Hepatocellular Carcinoma – N13-6335 and N12-5663

  • Under low power microscopy, smear pattern shows trails of smooth-edged, arborizing clusters of thickened trabeculae with peripheral endothelium (pathognomonic)
  • Under low power, smear pattern shows many loosely cohesive sheets of hepatocytes with transgressing vessels (highly suspect finding)
  • Monotonous, uniform hepatocytic cell population with subtle malignant features
  • Pseudoacinar formation in cell clusters
  • Nuclear-to-cytoplasmic ratio higher than in normal hepatocytes (>1/3)
  • Macroeosinophilic nucleoli
  • Reduced number of binucleated cells
  • Background free of bile duct epithelial cells
  • Reticulin stain demonstrates a loss of the normal 1 to 2 cells thick hepatic plate architecture
  • Iron stain fails to stain tumor cells in cases of hemochromatosis
  • α-fetoprotein is helpful if positive but often is not
  • Novel markers, such as glypican-3, glutamine synthetase and heat shock protein 70, are helpful if two out of three show positivity
1-10-5_N13-6335.WDHCC.jpg 1-10-6_HCC._reticulin_staining_with_staining_of_thickened_trabeculae.N13-6335..jpg
WDHCC: reticulin staining showing thickened trabeculae (>3 cells)
1-10-7_HCC._reticulin_stain_with_loss_of_staining._N13-6335.jpg 1-10-87_HCC_with_transgressing_vessels._N13-6335..jpg
WDHCC with transgressing, arboring vessels


Moderately to Poorly Differentiated Hepatocellular Carcinoma –N12-6639, NC13-322 and N11-12944

  • Low power smear pattern generally resembles that seen in well-differentiated tumors; however, there is a dyshesive tendency in poorly differentiated tumors
  • Peripheral endothelium is virtually pathognomonic
  • Transgressing vessels are suggestive, but cannot distinguish hepatocellular from renal cell carcinoma
  • Presence of intracytoplasmic bile is pathognomonic
  • Polygonal cells with central nuclei and prominent nucleoli with visible, granular to clear cytoplasm in moderately differentiated tumors; scant to no cytoplasm with greater degree of pleomorphism and mitotic activity in poorly differentiated tumors
  • Immunophenotype: low-molecular-weight CK (Cam 5.2), polyclonal carcinoembryonic antigen and CD10 (canalicular), and HepPar-1 and TTF-1 positive; α-fetoprotein variable; high-molecular-weight CK (AE1) negative
1-10-9_HG_HCC.N12-6639.jpg 1-10-10_HG._HCC.N12-6639.jpg
High grade hepatocellular carcinoma; note malignant cells making bile


Metastatic colonic Adenocarcinoma -- N12-85

  • Cigar-shaped, often palisaded nuclei
  • Variably prominent nucleoli, no macroeosinophilic nucleoli
  • Dirty necrosis in the background (key identification point)
  • Immunohistochemistry: CK20 positive, CK7 and CK19 negative, carcinoembryonic antigen positive
1-10-11_Met._colon_cancer.N12-85.jpg

Cytology service page
Warning: Display title "1-11 Pancreas FNA: M Pitman MD, J Misdraji MD, M Nutter CT" overrides earlier display title "1-10 Liver Cytology: M Pitman MD, J Misdraji MD, Marilyn Nutter CT".


Indications for cytology examination for pancreas
Procuring the specimen
Test platforms/specimen processing and triage
Reporting and Terminology


Basic cytomorphology


1-11-1_PPANC4-04._Benign_acinar_cells_low_power..JPG

Benign Pancreas – PPANC4-04 Key Cytological Features of benign acinar cells:

  • Cohesive, grape-like aggregates singly and attached to fibrovascular stroma
  • Scattered stripped naked nuclei
  • Basally located round nucleus
  • Finely granular chromatin
  • Small nucleolus; larger in reactive acinar cells
  • Abundant granular cytoplasm
  • Indistinct cell borders in clusters
1-11-2_PPANC-04._Normal_panc_duct.jpg

Key Cytological Features of Ductal Epithelium:

  • Flat, cohesive sheets with even nuclear spacing within sheets
  • Uniform, on-edge "picket-fence" arrangements
  • Round to oval nuclei with fine, even chromatin
  • Inconspicuous nucleoli
  • Non-mucinous cytoplasm
1-11-3_MN05-N08394._duodenum..JPG

EUS Contaminants


Duodenal Epithelium– MN05-N08394

  • Flat and cohesive monolayered sheet with a honeycomb pattern; occasionally papillary groups (intact villi), smaller groups and single cells
  • Non-mucinous glandular cells with brush border
  • Sporadically placed goblet cells appearing as “fried eggs” with a sheet
  • Lymphocytes (“sesame seeds”) in the epithelium
1-11-4_N13-6431._gastric_epithelium.jpg


Gastric Epithelium– N13-6431

  • Small sheets, strips and occasionally single cells and gastric pits
  • Visible mucin in foveolar cells, often apical mucin cups
  • Grooved naked nuclei, typically floating in extracellular mucin


Ductal Adenocarcinoma

  • Incidence: 11 per 100,000 ; 4th leading cause of cancer death in men and women
  • Age, Gender: Peak incidence 7th to 8th decade; M>F by 30%
  • Prognosis and Therapy: 5-year survival rate is 3-4%. Surgical resection is the treatment of choice.
  • Radiological Features: Hypodense mass with a poorly defined periphery and often a “double duct sign” from dilatation of both the pancreatic and bile ducts.


Key Cytologic Features: Ductal Adenocarcinoma

1-11-5_PPAN4-06._HGPDAC.JPG


High Grade Adenocarcinoma – PPAN4-06

  • Glandular smear pattern with ductal cells in variable amounts
  • Three-dimensional groups with nuclear crowding, overlap and loss of polarity
  • Obvious nuclear membrane irregularities, hyperchromasia, coarse chromatin and prominent nucleoli
  • Mitosis, necrosis and dyscohesion with single intact malignant cells
1-11-6_PPAN3-29.WD_PDAC..JPG


Well-Differentiated Adenocarcinoma – PPAN3-29

  • Loss of honeycomb architecture with nuclear crowding, overlapping, loss of polarity and uneven spacing ("drunken honeycomb")
  • Nuclear area variation (>4:1) within a single group of cells
  • Chromatin clearing and/or peripheral clumping (parachromatin clearing)
  • Abundant cytoplasmic mucin
  • Nuclear contour irregularities, often subtle


Neuroendocrine Tumor –MN07-R09706 and N13-6431

  • Incidence: ~2-5% of pancreatic neoplasms; ~50% functional and 50% nonfunctional
  • Age, Gender: Any age but most between 40-60 years; M=F
  • Prognosis and Therapy: Small neoplasms without adverse prognostic features are curable by surgical resection; prognosis is related to tumor size, mitotic rate, necrosis, extrapancreatic invasion, vascular invasion, and nodal or distant metastases
  • Radiological Features: Solid, well-circumscribed masses, usually small (<2cm), but may be large (>6cm); can be cystic
1-11-7_MN07-R09706._PanNET.JPG

Key Cytological Features: Pancreatic Neuroendocrine Tumor

  • Discohesive, single cell "solid-cellular "smear pattern
  • Uniform, monotonous population of cells with plasmacytoid features
  • Coarse, speckled, “salt and pepper” chromatin pattern
  • Nucleoli may be prominent
  • Dense, finely granular cytoplasm


Acinar Cell Carcinoma – PAN2-036

  • Incidence: ~1-2% of adult pancreatic neoplasms
  • Age,Gender: children<<adults; peak incidence, 7th decade; M:F:: 4:1
  • Prognosis and Therapy: directly related to tumor stage and is better than for ductal adenocarcinoma. Resection is treatment of choice.
  • Radiological Features: Solid masses with well demarcated borders; rarely cystic

Key Cytological Features: Acinar Cell Carcinoma

  • Solid-cellular smear pattern of monomorphic cells
  • Cellular clusters of various sizes and single cells (loss of organoid "grape-like Clustering of benign acinar tissue)
  • Stripped naked nuclei; +/- loose cytoplasmic granules (best noted on Hand E stain)
  • May be disarmingly bland, with a polygonal cell shape and low N:C
  • Coarse chromatin usually with prominent nucleoli, but not always granular cytoplasm, variably prominent


1-11-8_PAN2-036._ACC.jpg

Solid Pseudopapillary Neoplasm [SPN labeled slides]

  • Incidence: ~1-3% of all pancreatic malignancies; 6% of exocrine tumors and ~24% of all surgically resected cystic lesions in the pancreas
  • Age, Gender: ~90% women are in their 20’s; mean age is 28 years
  • Prognosis and Therapy: Prognosis is excellent with only 15% developing recurrence or metastases
  • Radiological Features: Well-circumscribed mass with solid and cystic components, usually in the pancreatic tail

Key Cytological Features: Solid-Pseudopapillary Neoplasm

  • Solid cellular smear pattern with or without branching and papillary cell clusters
  • Fibrovascular myxoid stromal papillae are characteristic Cells are relatively bland with little anisonucleosis and no mitotic activity
  • Nuclei are round to oval with frequent nuclear grooves or focal indentations and finely granular chromatin and inconspicuous nucleoli
  • Cytoplasm is typically scant and ill-defined but can be moderate with small perinuclear vacuoles or intracytoplasmic hyaline globules, best detected on air-dried smears
  • Smear background may be clean or filled with hemorrhagic cyst debris, foamy histiocytes and multinucleated giant cells
1-11-9_SPN_labeled_slides._SPN_smear.jpg

Cytology service page
Warning: Display title "1-12 Kidney FNA: R Tambouret MD, E Brachtel MD, R Arpin CT" overrides earlier display title "1-11 Pancreas FNA: M Pitman MD, J Misdraji MD, M Nutter CT".
Indications for Kidney Fine Needle Aspiration Cytology/Biopsy

Procuring the specimen
Processing the specimen
Report

Kidney FNA- Management

Basic Cytomorphology

Normal renal cells – N13-7430
Glomeruli – N12-9686
Renal cell carcinoma – C94-1636
Oncocytoma – N13-6827


Warning: Display title "1-13 Adrenal: R Tambouret MD, E Brachtel MD, R Arpin CT" overrides earlier display title "1-12 Kidney FNA: R Tambouret MD, E Brachtel MD, R Arpin CT".

  • Indications for cytology examination
  • Procuring the specimen
  • Test platforms/specimen processing and triage
  • Report


Basic cytomorphology

Normal adrenal cells – N13-6084
Pheochromocytoma – C91-C20757
Adrenal cortical carcinoma – C99-T12804
Metastases –N13-6638, C95-N3969 and C97-R25603

Cytology service page
Warning: Display title "1-14 Breast FNA: E Brachtel MD, A Ly MD, D Tetreault CT" overrides earlier display title "1-13 Adrenal: R Tambouret MD, E Brachtel MD, R Arpin CT".


Indications for cytology examination
Procuring the specimen
Test platforms/specimen processing and triage
Reporting and terminology


Basic cytomorphology

Benign Components – C93-17243
Fibroadenoma – C01-43583
Fat Necrosis – C95-1257
Papilloma –C94-17220
Gynecomastia – N11-11968
Papillary Carcinoma – N13-7402
Phyllodes Tumor – C98-11449
Ductal Carcinoma – Low grade: C02-6087 High grade: C01-33524
Lobular Carcinoma – C02-22969
Medullary Carcinoma – C92-2097


Triple Test


Reference- McKee, Grace T. Cytopathology of the Breast, MGH 2002 Fisher, Andrew H. Breast FNA, Cytologystuff through Hologic, 2013


Cytology service page
Warning: Display title "1-15 Lymph Node FNA: I Chebib MD, R Tambouret MD, D Kuebler CT" overrides earlier display title "1-14 Breast FNA: E Brachtel MD, A Ly MD, D Tetreault CT".

  • Indications for cytology examination
  • Procuring the specimen
  • Test platforms/specimen processing and triage
  • Report


Basic cytomorphology

Reactive Lymph Node– C95-32492
Granulomatous lymphadenitis – N13-4708
CLL/ SLL – C99-35197
Follicle center lymphoma– MN06-3065
Diffuse Large B-cell lymphoma – C95-D22979
Small cell carcinoma– N13-5133

Cytology service page
Warning: Display title "1-16 Bone and Soft Tissue Cases: I Chebib MD, D Kuebler CT" overrides earlier display title "1-15 Lymph Node FNA: I Chebib MD, R Tambouret MD, D Kuebler CT".

General

Indications for cytology examination
Procuring the specimen
Test platforms/specimen processing and triage
Reporting and terminology


Basic cytomorphology

Gout – MN09-F8915
Chordoma – MN09-D13495
Myxoid liposarcoma – N13-1062
Ewing’s Sarcoma – S90-b11855
Giant cell tumor of bone – 91-12413
Metastatic Lobular Carcinoma of the breast – MN10-4291

Cytology service page
Warning: Display title "1-17 Palpable Fine Needle Aspiration Biopsy: Procedure, Techniques, and Specimen Handling<b></b>" overrides earlier display title "1-16 Bone and Soft Tissue Cases: I Chebib MD, D Kuebler CT".

General

Amy Ly, M.D.

Indications for FNA
Procuring the Specimen
Test platforms/processing and triage

Please see separate organ sections for reporting and terminology details.

GOALS/EXPECTATIONS:

What you are expected to do: Pathology trainees will be expected to perform FNA procedures on patients and prepare specimens under supervision of an attending cytopathologist. Residents may perform procedures under supervision of an approved Cytology Fellow after Fellow has demonstrated competency. Trainee performance will be evaluated and documented.

Daily Schedule:

8am-9am: Attend Cytology Consensus Conference (may not happen every morning). Residents should ask the Cytology Fellows to be included in the group text pages.

9am-12pm: Be available and prepare for FNA procedures.* Review and signout with attending your assigned cytology specimens when not on an FNA procedure.

12pm-1pm: Attend Outs sessions or similar.

1pm-5pm: Be available and prepare for FNA procedures.* Review and signout with attending your assigned cytology specimens when not on an FNA procedure.

  • The Cytopathology division at MGH runs the Fine Needle Aspiration Biopsy Clinic located on Wang-270. The FNA Clinic sees patients in 45-minute appointments from 9am-noon and 1pm-5pm Monday-Friday (i.e. 9:00am, 9:45 am, 10:30am, etc.). No patients are seen during the noon-1pm lunch hour, or on weekends. Appointments are booked by the Cytopathology Main Desk (Diane White and Bernadette Femino). Introduce yourself to the Main Desk and ask them to page you with updates to the FNA schedule. Prepare for appointments by making sure the FNA Clinic supplies are stocked and reviewing the patient’s history in CAS/LMR prior to patient’s arrival.
  • We also occasionally perform FNA on in-patients at bedside. A cart containing a microscope and FNA kit are wheeled to the patient’s room for these procedures. The FNA cart is located in the Cytopathology Prep Lab (Warren-1).

HOW IS THE FNA ROTATION DIFFERENT FROM OTHER PATHOLOGY ROTATIONS?

You will directly interact with patients, talking with them and performing physical exams. You will learn how to obtain tissue samples from patients using a thin needle while they are awake. You will learn multiple methods to prepare tissue samples for evaluation. Unlike in the gross room, no scalpels are used and not all specimens are fixed in formalin. WHAT IS FINE NEEDLE ASPIRATION (FNA)?

FNA is a tissue sampling procedure that uses a thin needle (defined as 22 gauge or thinner). FNA is used to evaluate palpable superficial masses, both solid and cystic. FNA is also used to sample abdominal fat for amyloid testing. The needle is inserted through the skin into the mass to extract cells. The patient is awake during the procedure, but the biopsy site may be numbed with local injection of anesthetic such as lidocaine.

FNA can also be performed under image-guidance (e.g. ultrasound, CT) to evaluate deep-seated, nonpalpable radiologic abnormalities such as in the lungs or liver. FNA done using endoscopy or bronchoscopy to evaluate sites such as pancreas and mediastinal lymph nodes. The patient is often sedated in these settings and the procedures are performed by non-pathologists.

Because the needle used is so much thinner than the ones commonly used for core biopsy (which can be as large as 8 gauge), the tissue obtained in FNAs consists of tiny fragments that often cannot be discerned by the naked eye.

Review “Introduction” video on http://www.papsociety.org/fna.html.

Materials and Supplies

All the equipment needed to perform an FNA (see Table) is small and lightweight enough to be hand-carried in one container. As a result, FNAs may be performed virtually anywhere on demand. The equipment occupies only a small area of table space when laid out for specimen preparation.

Review “Equipment” video on http://www.papsociety.org/fna.html.

FNA Equipment List

1. Syringe holder (10 mL Cameco syringe pistol or equivalent)

2. Disposable sterile 10 mL plastic syringes

3. Disposable sterile needles with transparent hubs (23g and 25g, 1.0 to 1.5 inches long)

4. Alcohol swabs

5. Sterile gauze pads

6. Glass slides with frosted end for labeling

7. Fluid transport medium (e.g., sterile RPMI, saline, formalin)

8. Local anesthesia and needle/syringe to administer (e.g., 2% lidocaine, 27g/1 cc)

9. Alcohol fixative (commercial spray fixative or jar filled with 95% ethanol)

10. Gloves (preferably non-latex)

11. Pen/pencil for labeling slides (e.g., Leica pen, blue marking pencil)

12. Plastic slide holders or slide trays (for transporting slides)

13. Rubber-topped blood-draw tube for “flip” technique.

FNA Procedure for sampling a palpable mass

Steps for a successful fine needle aspiration (FNA):

Decide if an FNA should be performed Consent the patient for the procedure Position the patient and immobilize the lesion Sample the targeted lesion adequately Prepare the sample for evaluation, including appropriate allocation of material for ancillary studies as necessary Provide post-procedure instructions to the patient


Decide if an FNA should be performed

All patients presenting to us for an FNA have been referred by a clinician. Review the patient’s clinical history and relevant imaging studies before seeing the patient. Perform a focused physical examination to confirm that the lesion is indeed palpable and an FNA is clinically appropriate. While feeling the mass with your fingers, take mental notes on its size, shape, and relationship to any significant structures like large blood vessels. This information guides how you will approach sampling the lesion (e.g., the length of needle to use, vascular areas to avoid).

Sometimes the mass will be marked on the patient’s skin by the referring clinician.

If you have trouble finding the mass, the patient may be able to show you where it is.

During the brief examination, take a moment to ask whether the patient has any history of bleeding disorder or if s/he is on blood thinners.

If the lesion is not palpable or cannot be safely sampled, do not perform an FNA. An alternative is to evaluate the patient and perform the FNA procedure using ultrasound guidance. (See “FNA using Ultrasound” Supplement.)

Consent the Patient

Describe the FNA procedure in detail to the patient, including its purpose and potential complications. Allow the patient to ask questions. Confirm the patient’s name, date of birth, and site to be biopsied. Have the patient sign the procedure consent form.

Sample dialogue with a patient for obtaining consent for the FNA procedure:

“Hello Mr. Smith, I am Dr. Ly from the Department of Pathology. I understand that Dr. Jones has sent you here for a fine needle aspiration biopsy of a mass on your arm. Our goal is to determine the diagnosis for the mass. Let me explain what the procedure involves. Feel free to ask questions at any point.

I will use a very thin needle to sample the mass. The needle is the same size or smaller than the ones used for blood draws. I will insert the needle into the mass and move the needle back and forth for about 15-20 seconds. I usually do this 2 or 3 times, which means 2 or 3 separate needle sticks. I may need to do it a 4th time if I think additional material will help us make a diagnosis. We will take a small break after the 1st or 2nd needle stick so I can quickly check how much material we have by looking under a microscope. This is not to make a diagnosis, but rather it is a quantity check to make sure there is enough material to evaluate.

Every patient’s experience with this procedure is different. Most patients feel a pinprick when the needle goes through the skin just like during a blood draw. While the needle is moving back and forth, most patients feel a pulling sensation or dull pressure or soreness. I can inject lidocaine into the skin over the lump to numb the area. It will be an additional needle stick and you may feel a temporary burning sensation that lasts up to 30 seconds. If during the procedure you experience pain that you cannot tolerate, I will stop and take the needle out.

This procedure has a few minor risks that you should be aware of. The most common are bleeding and slight bruising. After each needle stick, my assistant will apply firm pressure with a clean gauze pad to minimize bleeding. Infection is another possible complication, but I clean the skin well with alcohol before each needle stick to minimize the chances of this happening.

Do you understand the purpose of this procedure and the risks involved? Do you agree to having this procedure? If so, please confirm for me your full name and date of birth, and sign this consent form.”

Prepare the Equipment

Universal safety precautions must be observed during the biopsy procedure and while handling the harvested tissue specimen.

You must prepare the tissue sample immediately before it dries/clots. You will make smears from the sample, and may rinse the needle and allocate material for special studies if necessary. Label several clean glass slides with at least 2 patient identifiers (e.g., name, date of birth, medical record number). Open a jar of alcohol slide fixative. Open a sterile test tube and fill it halfway with saline. Open a small jar of formalin. Place these materials on your table workspace.

Load a syringe onto the syringe holder and attach a needle. Commonly, 23g and 25g needles measuring 1.0 to 1.5 inches long are used. Choose the shortest needle that reaches the deepest area of the lesion from the skin. For example, if the bottom edge of the mass is 1 inch beneath the skin, choose a 1 inch needle, not a 1.5 inch needle. Loosen the needle cap and set the equipment down in a convenient location.

Position the Patient and Immobilize the Mass

Position the patient such that s/he is comfortable and the lesion can be palpated and immobilized (i.e. held fixed in place by the fingers of your non-dominant hand so it does not move around while you are sampling it). Ideally, have the patient lie on his back; this is a safe position in case of a vasovagal response and the patient passes out during the procedure. Support the patient’s body with pillows, rolled up sheets/towels, or foam shapes. Changing the patient’s body position can dramatically affect the accessibility of the lesion. Breast lumps are usually best appreciated with the patient’s arm raised above the head. Neck masses easily felt in the sitting position but may completely disappear when the patient lies on his back.

If the mass is beneath a band of skeletal muscle, position the patient such that the muscle is relaxed and pull or push the muscle aside. Inserting a needle through skeletal muscle is painful for patients, and will clog your needle, preventing you from obtaining a good sample.

Plan ahead how you will immobilize the mass – try different configurations with your fingers (of your non-dominant hand) on the mass. Also plan the angle at which your needle will be inserted into the mass. For many lumps, inserting the needle perpendicular to the skin surface is adequate. Clean the skin with an alcohol swab. If local anesthesia is to be given, start by injecting 0.5 cc to 1.0 cc of 2% buffered lidocaine subcutaneously at the biopsy site. Additional lidocaine can be given at any subsequent point if the patient is uncomfortable. Sensitive areas such as the nipple/areola complex should receive more lidocaine up front (e.g. 2 to 3 cc). Allow a few minutes for the local anesthesia to take effect. Caution: With small nodules (e.g. < 5 mm), injecting too much lidocaine can cause enough skin swelling that your fingers can no longer feel the mass distinctly.

For all patients, but particularly those who decline lidocaine, offer your hand and encourage them to squeeze it during the procedure. This helps to alleviate discomfort and pain.

Review “Special Problems,” “Technique,” and “Stabilizing the Instrument” videos on http://www.papsociety.org/fna.html.

Sample the Mass

Review “Needle Movement” video on http://www.papsociety.org/fna.html.

Once the mass is fixed with the non-aspirating hand, clean the skin with an alcohol swab at the planned needle entry site. Remove the loosened needle cap and stabilize the aspirating hand by resting the syringe barrel against the thumb or forefinger of the non-aspirating hand. A steady hand ensures precise needle placement. Push the needle through the skin into the mass in one motion, and pull back the syringe plunger to generate several cc of suction. At this point, it is no longer necessary to stabilize the aspirating hand. Maintain the vacuum until you are just about to remove the needle from the patient. With a straight wrist, quickly move the needle back and forth in a sawing motion (“excursions”) for no longer than 15-20 seconds (approximately 40-60 excursions) along the original needle trajectory. (For vascular lesions such as thyroid, 2 to 5 seconds is recommended.) Make sure the needle does not exit the patient. Each time the needle advances into the lesion, its cutting tip dislodges small tissue fragments; this cutting action is essential for a successful FNA. Slow needle action will yield less material, and no needle movement at all movement will yield a non-diagnostic sample in solid masses. The vacuum in the syringe helps tissue fragments travel up the needle shaft. Keep the needle tip within the mass to avoid diluting the sample with adjacent non-lesional tissue. As you perform your excursions, you may see material accumulating in the needle hub. If blood rapidly enters the hub, withdraw the needle immediately and apply pressure to the site with gauze.

Sampling with thinner needles (25g or 27g) is preferred for vascular organs like the thyroid, and for fibrous lesions like a fibroadenoma of the breast. When sampling a densely fibrotic mass, your excursions should be more forceful.

Review “Sampling of Different Nodule Parts” video on http://www.papsociety.org/fna.html.

An FNA procedure typically involves inserting the needle into the mass 2 or 3 times (“passes”) to obtain several samples. The center of the mass is often sampled on the first needle pass with the needle approximately perpendicular to the skin. You can try other areas of the mass on subsequent passes, especially if the initial material is necrotic, cystic, or non-diagnostic. Sample the mass along its long axis to obtain more cellular specimens.

To sample more than one area within the mass on one needle pass, withdraw the needle tip to a superficial location, then change its angle of entry to enter a different area of the mass. “Fanning” allows for sampling of a larger area: after each excursion, when the needle tip is in a superficial location, change its angle of entry slightly until the entire region of interest is sampled. Avoid changing direction when the needle is deep in the lesion. This results in tissue tearing and hemorrhage, which compromises the diagnostic yield of subsequent passes.

Remove the needle from the patient after the last excursion or when you see material or blood in the hub, which can occur in < 15 seconds. Release the vacuum in the syringe before withdrawing the needle from the patient. Withdrawing the needle from the patient when there is still negative pressure in the syringe will force aspirated material up into the syringe barrel, and it cannot be used to make smears (you can still retrieve it by rinsing the needle as described below). Hold firm pressure to the biopsy site with gauze for several minutes, longer if there is a history of coagulopathy or blood thinners. The patient or an assistant should perform this step, because the aspirator needs to prepare the sample immediately.

Prepare the sample

Make Smears

There are multiple ways of preparing direct smears from the aspirated material retrieved from the needle and needle hub. Because aspirated material will vary in quantity and quality from case to case, it is important to be familiar with several different techniques.

Review “Expulsion onto slide,” ”Flip Technique,” “Basic Smearing Technique,” “Dividing Material,” and “Problem Material” videos on http://www.papsociety.org/fna.html.

Fix the Smears

Generally, at least one alcohol-fixed and one air-dried smear should be made from each needle pass. The advantages of each fixation method are shown below. Air-dried smears should be dried quickly to avoid drying artifacts. When fixing with alcohol, submerge the smear in 95% ethanol immediately after it is made to avoid air-dry artifacts.

For information about making cell blocks from smears, see "Reserving Material for Ancillary Studies" and "Making a Cell Block from a Smear" on our sample preparation page.

Air-dried Smears Alcohol-fixed Smears
Useful for Rapid Evaluation? Yes; stain on-site with DiffQuik. Superior nuclear detail.
Yes; stain on-site with Toluidene blue Rapid on-site evaluation (if a modified Ultrafast Pap stain, toluidine blue, or rapid H&E stain used).
Yes; allows for evaluation of lesions with background material
Advantages Enhances cellular pleomorphism. Superior nuclear detail.
Fast and easy to perform. Less air-drying artifact and enlargement.
Better for evaluating background material and cellular cytoplasm (e.g., mucin, cartilage) Better for evaluating squamous lesions.
Better for visualizing some organisms such as mycobacteria (“negative images”).


Assess Specimen Adequacy

  Rapid on-site evaluation of smears can be performed.  This is the Cytology equivalent of frozen sections.
  Choose 1 or 2 cellular slides for immediate evaluation.  If air-dried, stain using Diff-Quik and do not coverslip.  If alcohol-fixed, stain using Toluidine Blue and coverslip.  Evaluate the slides under the microscope and determine whether the quantity and quality of the material present is sufficient for diagnosis.  Determine whether obtaining material for ancillary studies will be helpful (e.g. flow cytometry, cell block for IHC).

Diff-Quik Staining Procedure: 5 dips in methanol, 5 dips in DQ-I solution (with eosin), 5 dips in DQ-II solution (with methylene blue), 5 dips in tap water to rinse. Observe the stained material. If it is red/brown/orange, dip again in DQ-II and rinse in tap water. If the material is blue/purple, staining is adequate. Dry back of slide with paper towel and review it under the microscope without coverslip. Background material and cytoplasmic quality are accentuated with this stain. Nuclear membrane irregularities may not be as obvious as on alcohol-fixed material. Cells appear larger and more pleomorphic than if alcohol-fixed.

Toluidine Blue Staining Procedure: Remove slide from jar of alcohol and place on tabletop face-up (cellular material is on top surface). Using eyedropper, place 1-2 drops of Toluidine Blue solution onto slide. Coverslip and remove excess fluid using capillary action by tilting slide onto its edges. After allowing stain to penetrate for 30-60 seconds, dry back of slide and evaluate under microscope. Nuclei will appear dark blue with this stain. Background material and cytoplasmic quality are usually not well-visualized.

Waste Disposal: Discard used tap water and stains into dedicated plastic container using funnel. Container is located under the counter in left cabinet.

How to Handle Cyst Aspirations

If the mass is cystic, you will see fluid filling the syringe barrel under negative pressure. Aspirate as much fluid as possible from the cyst; pushing on the mass can assist with this. The fluid can be discarded if appropriate (e.g., clear fluid from a breast cyst) or deposited directly into a container for subsequent processing. The patient is re-examined, and any residual mass sampled on a subsequent pass.

Avoid performing an FNA on a given site more than 3 to 4 times at one clinic visit. Repeated biopsies increase tissue hemorrhage, reducing diagnostic yield. It is better to have the patient return in several days for a repeat FNA.

Rinse the Needle and Reserve Material for Ancillary Studies

To harvest as much of the sample as possible, rinse the needle into a liquid medium. Place the needle tip in a container of medium and draw a small amount of liquid into the syringe by pulling back on the plunger. Then expel it back into the container by pushing in the plunger. Gently repeat this a few times. Excessive force may mechanically damage cells.

The needle can be rinsed with several different media. We use saline, formalin, and/or SurePath fixative. The medium you choose will depend in part on what ancillary studies you anticipate will be needed. In our lab, the most versatile sample is the needle rinse in saline.

Type of Preparation Ancillary Test
Flow Cytometry Cell Block Cytogenetics (Karyotyping) FISH DNA-based Molecular Test Immuno-histochemistry
Smear No Yes No Yes Yes Yes
Formalin-fixed cell block No Yes No Yes Yes Yes
ThinPrep or SurePath fixative No Yes No Yes Yes Yes
RPMI/saline Yes Yes Yes Yes Yes Yes
needle rinse

Post-Procedure Information for The Patient

Evaluate the patient before allowing her to stand up. If she is dizzy or light-headed, have the patient remain supine longer.

Give the patient a copy of “Fine Needle Aspiration Biopsy; Post-Procedure Instructions for Patients.”

Example of parting words to the patient:

“The final report should be ready in a few days and the results will go directly to Dr. Jones, who will then contact you.  The report may take a little longer if additional tests are needed.  Here are some instructions and information for you to take with you.  You can go about your daily routine, including showering and swimming.  If you have a small amount of bleeding later today, apply an ice pack for 20 minutes to help stop the bleeding.  You might feel some soreness; this will go away in a few days.  In the meantime, take Tylenol if you are uncomfortable.  Also, the lump might seem bigger than it was before; this is due to some swelling from the procedure.  The lump will return to its original size within a week or so.  If you see signs of infection such as fever and redness/pain/discharge at the biopsy site, or if there is persistent bleeding, call Dr. Jones’ office.


Variations on Biopsy Technique

For information on "feeling with the needle", and further info about technique variations and preparing/procuring the specimen see our procuring the specimen page.

Zajdela Technique

The FNA biopsy can be performed without suction (the Zajdela or “French” technique) using only the needle or the needle attached to a syringe, with the plunger either pulled out part way or completely removed. The needle hub or syringe is held like a pen in the aspirating hand, which is stabilized by resting the wrist on an available fixed surface (e.g., exam table, a part of the patient’s body). Without suction, the amount of material harvested is typically lower, but the preparations are also less bloody. This method places the aspirating hand closer to the sampled mass, which allows more needle control and superior tactile perception of the tissues penetrated by the needle. It is especially useful when sampling very small or very vascular lesions.

Review “Zajdela’s Technique” video on http://www.papsociety.org/fna.html.


Sampling two or more distinct areas in a mass in one needle pass

More than one area in a mass may be sampled using just one needle pass. Sample the first area as usual. Then withdraw the needle tip to a superficial location (e.g. dermis) while maintaining vacuum and without exiting the patient. Change the needle’s angle of entry to redirect it to a different area and sample by performing excursions. Repeat as required.


Sampling a large region in a mass in one needle pass

A larger area in a mass may be sampled using just one needle pass using a technique called “fanning.” After each excursion when the needle tip is in a superficial location, change its angle of entry slightly until the entire region of interest is sampled. Changing the needle direction while the needle is deep in the lesion is to be avoided as it can cause tissue tearing and hemorrhage, which will then compromise the diagnostic yield of subsequent passes.


How can I practice sampling masses by FNA?

You can practice sampling with the syringe holder, with or without ultrasound, using phantom body parts. We have a simulated neck and a simulated breast in the FNA Clinic for this purpose.

You can practice French technique for sampling by taking home a syringe and a few needles. Some suggested surrogate targets: fruits, vegetables, raw meat.


POTENTIAL Complications

Minor pain, bleeding, and bruising are most common. A significant hematoma develops occasionally. Malignant lesions tend to bleed more than benign ones. Stop any bleeding by applying firm pressure to the biopsy site for several minutes. This is sufficient even in patients with coagulopathy. Some patients experience a vasovagal response; prevent falls in case of fainting by positioning the patient supine on the exam table.

Pneumothorax can rarely occur when aspirating a lesion near the chest wall. The patient will experience immediate chest and/or shoulder pain. The risk is greatest in thin patients. Choose a needle trajectory that is tangential to the rib cage to reduce the risk.

Table 8.4 frequency of Pneumothorax as a Complication of Fine Needle Aspiration (FNA) of Superficial (Palpable) Lesions

Authors Cases of pneumothorax Total FNAs Incidence of pneumothorax (%)
Catania et al24 13 74,000 1:5693 (0.018)
Gateley et al25 7 not given 1:1000 (0.10)
Goodson et al26 1 285 1:285 (0.35)
Kaufman et al27 4 1666 1:417 (0.24)

Needle stick injury to the aspirator may occur whenever the needle tip is exposed. Avoid such injuries with vigilance and attention to the location of the needle tip at all times. Always exercise universal precautions.


Management of Adverse and Unexpected Events

1) If the needle enters an artery, bright red blood shoots into the syringe barrel in a pulsatile fashion. Immediately remove the needle from the patient and apply firm pressure with gauze to the site for several minutes. Submit the blood in the syringe for cell block preparation.

2) If the patient experiences neurologic symptoms (e.g., radiating pain or tingling), stop the procedure and remove the needle. Prepare any sample already procured and observe the patient. This condition is transient. Wait for the symptoms to resolve before attempting additional sampling. If the patient experiences extreme/intolerable pain (e.g., schwannomas are quite painful when aspirated), abort the procedure and suggest repeat sampling with sedation.

3) If the patient has a change in heart rate or experiences difficulty breathing, call a code (x6-3333).

4) If the patient moves unexpectedly during the procedure, you may accidentally stick yourself with the needle. Reduce the risk of a needle stick injury by keeping the needle tip inside the patient and removing the needle from the patient only when it is safe to do so.

5) If you are stuck by a contaminated needle: a) stay calm, b) wash injury with soap and water, c) pat dry and apply bandage, d) apply pressure through bandage if still bleeding, and e) call Occupational Health for instructions (x6-2217).

6) Document any patient complications of FNA and their resolution in the medical record.


Where to Drop off specimens and FoRMS for ancillary studies

Cytology Requisition- Cytology Lab (yellow form)

Cell Block- Cytology Lab (same yellow form as Cytology Requisition)

Flow Cytometry- Cytology Lab (fill out separate form available in Lab)

Microbiology- Cytology Lab (fill out separate form available in Lab)

Cytogenetics- Frozen section lab (Blake 3). Specimen must be put in media available from grossing area.

EM- Currently no separate EM form used. Obtain a small vial of glutaraldehyde from the frozen section lab (Blake 3) in freezer compartment of small fridge. Allow the media to thaw 5-10 min at room temperature, and then deposit the specimen in the media. Photocopy the Cytology Requisition, place the copy in a specimen bag with the sample, and leave the bag in a small white container labeled “EM for Warren 5” on shelf inside the fridge door.



ADDITIONAL forms

Completed FNA Template - leave with Souad Mouni for typing (Warren 105).

CYTOLOGY FELLOWS ONLY: INSTRUCTIONS FOR PATIENT FOLLOW-UP You will keep an individual log of the FNA procedures you perform during your Cytology Fellowship year. You will also be expected to contact each patient by telephone within 5 working days of the FNA procedure to ask the patient about his/her post-procedure symptoms and their management/resolution, and to obtain feedback about their overall experience with the FNA procedure.


Sample dialogue with patient at the end of FNA appointment:

CytoFellow: Would you mind if I called you in a few days to check in and see how you are doing?

Patient: Okay.

CytoFellow: What would be a good phone number for me to reach you at?

Patient: 617-555-1212.

CytoFellow: Thank you.

Sample follow-up telephone dialogue with patient after FNA procedure:

Cyto Fellow: Hi Mr. Smith. This is Dr. Kerr from MGH. I performed the FNA biopsy procedure on your [body site] last Wednesday. I am calling to see how you are doing. Did you have any discomfort or pain at the biopsy site? How was your overall experience with our FNA team/the biopsy procedure? Etc.


Document the following information using an Excel file spreadsheet using the corresponding column headings (underlined):

1. Patient MRN

2. Date of FNA procedure

3. Body site sampled

4. Was patient amenable to being called?

5. Date of phone call to patient

If patient was successfully contacted, record the following:

6. Complications

When the patient got home, did s/he experience pain (if so, record severity using scale of 1 to 10), bleeding, or bruising? If so, how did s/he treat the symptom(s)? Did symptoms resolve? (e.g. “I had pain 6 out of 10 that evening, but it went down to a 2 out of 10 after I took some Tylenol, and was gone the next morning.”)

7. General Comments

Patient feedback regarding overall experience (e.g. “I was happy that you could see me so soon.”)


Sample Excel sheet

Patient MRN

Date of FNA

Body site

Ok to call?

Date of Phone Call

Complications (pain, bleeding, bruising)

General Comments

9406822

1/1/2012

Left arm

Yes

1/4/12

Pain overnight (7/10), relieved with ice pack, no pain next day, slight bruising

“Dr. Chebib was really nice.” “I appreciate you checking in.”



Recommended Reading


Cibas, E. S. and B. S. Ducatman (2009). Cytology : diagnostic principles and clinical correlates. Philadelphia, PA, Saunders/Elsevier.


Ali, S. Z. and E. S. Cibas (2010). The Bethesda system for reporting thyroid cytopathology : definitions, criteria, and explanatory notes. New York, Springer.


Solomon, D. and R. Nayar (2004). The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes, Springer.


Bibbo, M. and D. Wilbur (2008). Comprehensive Cytopathology: Expert Consult: Online and Print, Elsevier Health Sciences.


Gupta, P. and Z. Baloch (2011). Cytohistology: Essential and Basic Concepts, Cambridge University Press.


DeMay, R. M. (2012). The Art & Science of Cytopathology, ASCP Press.


Cytology service page

Rotation 2 (2 weeks) Rotation-2 curriculum is advanced, and intended to be completed during two weeks of AP-2. Warning: Display title "2-1 Cytology laboratory management" overrides earlier display title "1-17 Palpable Fine Needle Aspiration Biopsy: Procedure, Techniques, and Specimen Handling<b></b>".


Regulatory agencies and guidelines


Laboratory Inspections Critical values in cytology: MGH Policy Quality management plan

a. Quality control/quality assurance

  • 10% rescreen
  • Retrospective rescreen
  • Cytologic-histologic correlation
  • Annual statistics
  • Workload records

b. Competency assessment

c. Proficiency testing

d. Continuing Education

e. Performance evaluation

Policy and procedure manuals

Billing Cytology Laboratory Budget Operations

  • Salary
  • Employee compensation
  • Employee benefits
  • Expenses
  • Lab
  • Office
  • Service Contracts
  • Rentals or Leases
  • Regulatory fees and permits
  • Maintenance
  • Telephone
  • Laundry
  • Freight
  • Revenue
  • Cost per test
  • Volume
  • Inpatient
  • Outpatient


Capital

  • Purchase
  • Reagent Rental
  • Lease

Cytology service page
Warning: Display title "2-2 Gyn Cytology" overrides earlier display title "2-1 Cytology laboratory management".

HPV Testing Methods; additional tests

  • Qiagen Hybrid Capture II : RNA:DNA Hybrid Capture
  • Cervista: Invader Technology
  • Roche Cobas 4800 Real-Time PCR
  • Tigris Aptima: mRNA hybrid capture
  • In situ Hybridization
  • Biomarkers: -p16INKA4a/CINtec Dual Stain

Image analysis assisted screening

Guidelines for management of patients with abnormal cervical cytology results

Advanced gyn cytomorphology cases:

  • HSIL variants/mimics
  • Adenocarcinoma variants/mimics
  • Radiation change

Cytology service page
Warning: Display title "2-3 Immunochemical stains in cytopathology" overrides earlier display title "2-2 Gyn Cytology".

Immunochemistry is used frequently in the work up of cytology samples, but given that most immunochemical staining protocols were developed for histologic sections and controls are usually histologic tissue sections, one needs to be aware of the factors that will impact immunocytochemical stains.

For a given cytologic preparation (cell block, direct smears, liquid based cytology) the issues with immunochemical stain will vary.

Cell block

Direct smear

Liquid based cytology


Cytology service page
Warning: Display title "2-4 Fluids: Ancillary testing" overrides earlier display title "2-3 Immunochemical stains in cytopathology".

Immunocytochemistry panels

Molecular pathology


Cytology service page
Warning: Display title "2-5 Urine: Ancillary testing" overrides earlier display title "2-4 Fluids: Ancillary testing".

Point of care tests

Immunocytochemistry panels

FISH


Cytology service page
Warning: Display title "2-6 Pancreatic cytology" overrides earlier display title "2-5 Urine: Ancillary testing". Cyst analysis

Ancillary testing

Immunocytochemistry panels

Molecular pathology


Cytology service page
Warning: Display title "2-7 Respiratory cytology: Ancillary testing" overrides earlier display title "2-6 Pancreatic cytology".

Microbiology cultures

Immunocytochemistry panels

Molecular pathology


Cytology service page
Warning: Display title "2-8 Thyroid cytology: Molecular testing" overrides earlier display title "2-7 Respiratory cytology: Ancillary testing".



Cytology service page
Warning: Display title "2-9 Lymphoid lesions" overrides earlier display title "2-8 Thyroid cytology: Molecular testing".

Advanced cytomorphology

Flow cytometry

Molecular testing


Cytology service page
Warning: Display title "2-10 Thymus and mediastinum" overrides earlier display title "2-9 Lymphoid lesions".


Cytology service page

Welcome to Cytology

Cytopathology is considered a subspecialty of anatomic pathology but in reality the discipline touches on all areas of anatomic pathology, albeit from the vantage point of the individual cell rather than tissue. The cytopathology laboratory functions separately but in parallel with the other anatomic pathology and clinical pathology labs. Correlation of cytopathology findings with test results obtained on concurrent tissue samples and other ancillary tests (biochemical and molecular) helps to improve diagnostic accuracy. Correlation with clinical and radiologic findings is also important. Residency training in cytopathology trains residents to be competent using a stepwise process for each organ system:

  • Indications for cytological examination
  • How to procure the specimen
  • Specimen processing
  • Test platforms used
  • Reporting terminology
  • Cytomorphology of normal cells and pathologically altered cells


The learning goals are in tune with the pathology milestones. The resident is expected to be at level 1 at the start of residency. Therefore the learning objectives are divided into the levels 2, 3 and 4 to correlate with the milestones. Residents may advance at a more or less accelerated pace through these levels.